BIOPHARMACEUTICAL MANUFACTURING - Risk Management Applications in Pharmaceutical and Biopharmaceutical Manufacturing - page 358

the Committee for Veterinary Medicinal Products (CVMP). (2004/C24/03). Avail-
able at http://www.emea.europa.eu/pdfs/human/bwp/TSE%20NFG%20410-rev2.pdf.
Accessed May 2011.
10. Geigert J. The Challenge of CMC Regulatory Compliance for Biopharmaceuticals.
New York, NY: Kluwer Academic/Plenum Publishers; 2004.
11. ICH Q5A (R1), Viral Safety Evaluation of Biotechnology Products Derived From
Cell Lines of Human or Animal Origin.
12. ICH Q5B, Quality of Biotechnological Products - Analysis of the Expression Con-
struct in Cell Lines Used for Production of r-DNA Derived Protein Products.
13. ICH Q5D Quality of Biotechnological Products - Derivation and Characterization of
Cell Substrates Used for Production of Biotechnological/Biological Production.
14. 5.1.7 Viral safety. European Pharmacopoeia (Ph. Eur.).
15. Food and Drug Administration 1993 Points to Consider in the Characterization of
Cell Lines Used to Produce Biologicals, Rockville, MD.
16. U.S. National Archives and Records Administration. 2012, Code of federal regu-
lations. Title 21. CFR 601.2(a). Applications for biologics licenses; procedures for
filing.
17. Bates R. Downstream processing. In: Ozturk SS, Hu W-S, editors. Cell Culture Tech-
nology for Pharmaceutical and Cell-Based Therapies. Oxford, UK: Taylor and Francis
Group, LLC; 2006. p 439-482.
18. Stanbury PF, Whitaker A, Hall SJ. Principles of Fermentation Technology. 2nd:
Burlington, MA, Butterworth and Heinemann Publishers; 2000.
19. Seewoester T. cell separation and product capture. In: Ozturk SS, Hu W-S, editors.
Cell Culture Technology for Pharmaceutical and Cell-Based Therapies. Oxford, UK,
Taylor and Francis Group, LLC; 2006. p 417-438.
20. Cacciuttolo MA, Shane E, Oliver C, Tsao E, Kimura T. Scale-up considerations for
biotechnology-derived products. In: Levin M, editor. Pharmaceutical Process Scale-
Up. New York, NY, Marcel Decker, Inc; 2001. p. 95-114.
21. PDA Technical Report No. 15, Validation of Tangential Flow Filtration in Biophar-
maceutical Application.
22. PDA Technical Report No.14, Validation of Column-Based Chromatography Pro-
cesses for the Purification of Proteins.
23. Moreton C. Functionality and performance of excipients in quality-by-design world
part 4: obtaining information on excipient variability for formulation design space.
Am Pharm Rev 2009;12(5):28-33.
24. United States Pharmacopeia/National Formulary. Rockeville: United States Pharma-
copeial Convention; 2009.
25. Merrell PH, I Silverstein. Inside IPEC-Americas: evaluating excipient stability.
Pharm Technol 2009;33(9):74-75.
26. Cromwell MEM. Formulation, filling and packaging. In: Ozturk SS, Hu W-S, editors.
Cell Culture Technology for Pharmaceutical and Cell-Based Therapies. Taylor and
Francis Group, LLC; 2006. p 483-522.
27. DeGrazio FL. Parenteral Packaging Concerns for Drugs. Genetic Engineering &
Biotechnology News. Vol. 25 21. New Rochelle, NY Mary Ann Liebert, Inc. pub-
lishers; 2005.
28. SEC. 501. [351] (a)(1)(3). Federal Food, Drug, and Cosmetic Act.